For how we live.
In 1,095 high-risk abdominal-surgery patients, targeting each person's own cardiac index during the operation left the rate of major complications essentially unchanged — 44.3% versus 46.9%.
The phase 3 RT CHARM trial found a three-week course of radiation after mastectomy was no worse than the standard five-week course for reconstruction complications, at 12.3% versus 10.2%.
Across 10 US children's hospitals and 697 patients, reoperation for recurrent twisting was rare either way — but laparoscopic repair carried lower odds of surgery for later bowel obstruction.
In the Nordic SWEDEGRAFT trial, the no-touch vein-harvesting technique left the rate of death, heart attack, or repeat procedures at 19.8% versus 20.4% through seven years — a difference indistinguishable from chance.
A post hoc analysis of the BAMBINI trial asked whether losing too much weight could backfire on fertility in PCOS. It did not: every degree of weight loss was linked to a better chance of ovulating.
ROAM/EORTC-1308, an independent phase 3 trial, randomised 157 patients after complete brain-tumour removal; adjuvant radiotherapy improved five-year disease-free survival, but the benefit's confidence interval was wide.
A single-surgeon randomised trial of 180 knees found small but statistically supported gains for robot-assisted functional alignment over conventional mechanical alignment at two years.
A final order classifies the flushing and storage solution for vascular autografts as Class II with special controls, codifying a 2023 De Novo decision on Marizyme's DuraGraft and setting the bar for future copies.
In the publicly funded SWOG S1600 trial, specialised immunonutrition before and after radical cystectomy left 30-day complication rates essentially unchanged: 62% versus 58% on a standard drink.
Cleared on 10 July under NDA 218579, the Provepharm agent fluoresces in near-infrared light to map vessels, perfusion and lymph nodes during surgery. Efficacy rests on studies of an earlier formulation.
A new draft guidance sets out the agency's current thinking on the non-clinical and clinical data it expects in premarket submissions for robotically-assisted surgical devices. Comments are due 24 November.
In 410 German women, 68% who had liposuction met the pain-reduction target at 12 months versus 8% on conservative therapy. Serious adverse events were higher after surgery.
The VITAL trial randomised 2,508 patients aged 50 and older to propofol-based or inhaled anaesthesia and found no difference in days alive and at home at 30 days, or in death, delirium or major complications.
In the SOLARIO trial, patients who got local antibiotics at surgery did no worse on a short systemic course than a long one, and reported far fewer side effects. The comparison was independently funded.
Carpal tunnel syndrome is median-nerve compression at the wrist. Cochrane reviews find steroid injections clearly help for about a month, while surgery beats non-surgical care at three and six months.
A Cochrane review of 24 trials found surgery beats non-surgical care at stopping an ingrown toenail coming back; adding phenol to the operation cut recurrence from 41% to 14% in the one head-to-head study.
A landmark trial found men could safely delay repair of a minimally symptomatic groin hernia. Over the following decade, though, most crossed over to an operation as symptoms grew.
The Hypotension Prediction Index warns anaesthetists before blood pressure falls. Three 2026 trials find a plain mean-pressure alarm does the same job, and the algorithm's benefit tracks how hard clinicians treat.
Fighting after the 2021 coup concentrated where hospital access was already worst. The population living with both poor access and intense conflict rose from 0.4 to 3.1 million in three years.
Tranexamic acid cut postpartum haemorrhage in placenta praevia. Dapagliflozin nearly halved acute kidney injury after cardiac surgery. The effect sizes are very different, and so is how much to trust them.
The procedure breaks the thigh bones and slowly pulls them apart over months. It is major orthopaedic surgery with a real complication rate, not a lifestyle upgrade.
A 293-woman Dutch trial found more women reported improvement at 12 months with perioperative oestriol cream than placebo. Anatomical success, surgical success and reintervention were unchanged.
ITACS randomised 955 anaemic adults to intravenous iron or placebo before elective cardiac surgery. Fewer patients needed a transfusion, but the primary benefit was a median of one day alive and at home.
RACER-Knee masked patients with sham incisions and found a Forgotten Joint Score difference of −1.5 points at 12 months (P=0.62) — while the robotic operation cost more.
The first randomised trial to pit surgery against the natural course of big-toe arthritis found fusion cut walking pain to 1.3 on a 10-point scale at one year, versus 5.7 with watchful waiting.
REMEASURE randomised 73 patients to Kono-S anastomosis or mesenteric resection after ileocolic surgery for Crohn's disease; endoscopic recurrence at six months was 33% versus 32%.
In a Chinese phase 2–3 trial, neoadjuvant chemotherapy, lenvatinib and a PD-1 antibody before liver surgery lifted median event-free survival to 18.0 months from 8.7. The survival signal was not yet conclusive.
In 2,286 patients with sleep apnea undergoing major surgery, a measure of how deeply and how long oxygen fell — not the apnea-hypopnea index — tracked 30-day cardiovascular events and death.
A network meta-analysis of 41,084 surgical patients over 60 ranked 52 drug interventions. Dexmedetomidine held up after high-risk trials were excluded; almost nothing changed length of stay or mortality.
A small prospective cohort followed 62 reconstructions for a quarter century. The graft type made no difference, and the uninjured comparison group dropped out of sport faster.